Navigation Links
Src Inhibitors in Breast Cancer Therapy

Estrogen, which binds estrogen receptor alpha (ER-alpha), is a risk factor for breast cancer development. However, one-third of new breast cancers lack detectable ER-alpha .

These ER-alphanegative cancers are more aggressive and have a worse prognosis than do ER-alphapositive breast cancers, and have been thought to be estrogen independent.

In a study appearing online on July 12 in advance of publication in the August print issue of the Journal of Clinical Investigation, Joyce Slingerland and colleagues from the University of Miami shed further light on the mechanisms regulating ER-alpha expression levels during breast cancer.

In their study of 250 primary breast cancers, the authors found that ER mRNA levels overlap considerably between ER-alphapositive and ER-alphanegative breast cancers.

This lack of correlation between ER-alpha mRNA and protein levels pointed to the existence of important post-transcriptional control of ER-alpha expression.

They found that ER-alphanegative primary breast cancers and cell lines showed increased levels and/or activity of the protein Src, which cooperates with estrogen to activate ER-alpha breakdown via proteolysis.

In line with this finding, Src inhibition was shown to impair estrogen-stimulated ER-alpha proteolysis. The data raise the possibility that for at least a subset of ER-alphanegative breast cancers, Src may stimulate estrogen-dependent ER-alpha degradation, resulting in a lack of ER-alpha detection, and more aggressive tumor growth.

The authors conclude that their study provides a rationale for the use of Src inhibitors in breast cancer therapy.

AUTHOR CONTACT: Joyce M. Slingerland University of Miami Miller School of Medicine, Miami, Florida, USA. Phone : (305) 243-7265; Fax: (305) 243-4787; E-mail: jslingerland@med.miami.edu


'"/>




Page: 1

Related medicine news :

1. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
2. LipB Protein Inhibitors Help To Fight Against TB
3. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
4. ACE Inhibitors For Vascular Disease Patients
5. Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer
6. Consensus on "Combination Therapy" for Breast Cancer
7. Breast cancer treatment to be determined by gene test
8. Breast Feeding prevents obesity later on in life
9. Breast milk is essential
10. Breast Cancer Surgery Causes Psychological problems
11. Breast cancer evidence
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology: